Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While sales of key drugs Vivitrol and Aristada continue to grow rapidly, Alkermes' overall revenue growth came in much weaker than expected. As a result, management dialed back its revenue growth expectations for the full year. However, containment efforts helped the company to beat expectations on the bottom-line.
Data source: Alkermes. GAAP = generally accepted accounting principles.
Image source: Getty Images.
Source: Fool.com
Alkermes plc Stock
€42.58
-1.910%
The stock is one of the favorites of our community with 23 Buy predictions and 1 Sell predictions.
As a result the target price of 46 € shows a slightly positive potential of 8.03% compared to the current price of 42.58 € for Alkermes plc.
